Canine cutaneous melanocytic tumours: significance of β-catenin and survivin immunohistochemical expression.

Abstract

BACKGROUND: Recent investigations have highlighted the controversial role of Wnt/&#x3b2;-catenin pathway activation in human cutaneous melanoma. Survivin has been proposed as a valid prognostic marker for invasive and metastatic melanomas and lymph node melanoma metastasis in human cutaneous melanoma and is a promising therapeutic target. HYPOTHESIS/OBJECTIVES: Our aim was to investigate the immunohistochemical expression of survivin and &#x3b2;-catenin in canine cutaneous melanocytic tumours, in order to understand their prognostic significance. METHODS: Twenty-one melanocytic tumours (10 melanocytomas and 11 melanomas) were investigated by immunohistochemistry using specific anti-survivin and anti-&#x3b2;-catenin antibodies. A semi-quantitative method was used to analyse the results; &#x3b2;-catenin immunolabelling in neoplastic cells was evaluated as cytoplasmic, membranous or nuclear. The number of survivin-positive cells was counted within ~1000 neoplastic cells. Results were related to histopathological features, evaluated in haematoxylin- and eosin-stained slides, and to the clinical data obtained through a telephone survey with referring veterinarians. RESULTS: Despite a low level of expression in the majority of cases, &#x3b2;-catenin was found to be correlated strongly with malignant behaviour (P < 0.01). An overexpression of nuclear survivin was statistically related to histological features of malignancy, presence of metastasis and death related to melanoma spread (P < 0.01). CONCLUSIONS AND CLINICAL IMPORTANCE: The low nuclear &#x3b2;-catenin expression, mainly found in metastatic cases, would indicate that &#x3b2;-catenin activation may have only limited importance in the development or progression of canine cutaneous melanoma. The correlation of nuclear survivin expression with malignancy would indicate that survivin is possibly a useful prognostic marker and therapeutic target in canine melanoma patients.